Literature DB >> 33161454

Ixazomib and lenalidomide maintenance therapy in multiple myeloma.

Ricardo D Parrondo1, Victoria Alegria1, Vivek Roy1, Taimur Sher1, Asher A Chanan-Khan1, Sikander Ailawadhi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33161454     DOI： 10.1007/s00277-020-04340-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

1.  Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.

Authors:  Juraj Sokol; Tomas Guman; Juraj Chudej; Monika Hlebaskova; Natalia Stecova; Lubica Valekova; Monika Kucerikova; Jan Stasko
Journal:  Ann Hematol       Date:  2021-09-22       Impact factor: 3.673

Review 2.  Future Directions in Maintenance Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Jens Hillengass; Philip L McCarthy
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.